Login to Your Account



Clinic Roundup


Wednesday, November 13, 2013
• Galectin Therapeutics Inc., of Norcross, Ga., said five of the eight patients have been enrolled and infused in the first cohort of its blinded Phase 1 trial of GR-MD-02 for patients with nonalcoholic steatohepatitis (NASH or fatty liver disease) with advanced fibrosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription